Screener
Eton Pharmaceuticals, Inc. ETON Uridine Triacetate — Other Commitment
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Eton Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:OtherCommitment.
The source filing: Eton Pharmaceuticals, Inc.’s 10-K, filed March 19, 2026.
- Filed
- Mar 19, 2026, 4:15 PM EDT
- Fiscal year
- FY2026
- Accession
- 0001437749-26-009059
In January 2026, the Company entered into a licensing and supply agreement for the U.S. marketing rights for an ultra-rare disease metabolic product candidate. Under the terms of the licensing and supply agreement, the Company paid $1,000 upon execution of the agreement and will pay seller $1,000 upon approval of the Abbreviated New Drug Application and commercial launch. The Company will pay profit sharing of 30.0% on net sales of the product candidate.
Item 1A. Risk Factors
FAQ
- What is Eton Pharmaceuticals, Inc.'s uridine triacetate — other commitment?
- Eton Pharmaceuticals, Inc. (ETON) reported uridine triacetate — other commitment of $1M in Q1 2026.
- What does uridine triacetate — other commitment mean?
- This metric captures miscellaneous contractual obligations or contingent liabilities associated with a specific product segment that fall outside of standard operating expenses or marketing rights payments. These commitments may include minimum purchase requirements, research and development funding obligations, or other long-term service agreements. Tracking these items is essential for understanding the total financial burden and potential future cash flow requirements tied to a specific asset.
Ask your AI about Eton Pharmaceuticals, Inc.'s uridine triacetate — other commitment.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude